Infectious Disease
PHASE2
● Phase II
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
ClinicalTrials.gov
Published March 27, 2026
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07144293 ↗
This Phase II study evaluates the safety and efficacy of dasatinib and quercetin (D+Q) in improving physical function among individuals aged 50 or older with HIV who are frail or prefrail. The study enrolled 82 participants on stable antiretroviral therapy with viral suppression. Participants were randomized to receive either D+Q or placebo in six cycles over 12 weeks, followed by a 12-week monitoring period. The primary endpoints include the occurrence of Grade 2 or higher adverse events (AEs), premature treatment discontinuations, and changes in gait speed on a 4-meter walk. Although specific statistical outcomes are not yet reported, the study aims to assess whether D+Q can significantly enhance physical function in this population. Secondary endpoints and long-term effects are also under evaluation. Safety data will focus on the incidence of AEs and any treatment-related discontinuations. The results of this trial could inform future therapeutic strategies for managing frailty in older adults living with HIV.
AI Accuracy Review: 9/10
· Auto-published
Imagine living with HIV for over a decade and facing the daily challenges of frailty as you age. This is the reality for many older adults, who often find that their physical strength and ability to perform everyday tasks diminish over time. A new clinical trial is exploring whether a combination of two drugs, dasatinib and quercetin, can help improve physical function for these individuals. In this study, 80 participants aged 50 and older will receive either the drug combination or a placebo over 12 weeks. The goal is to see if this treatment can enhance their ability to walk and carry out daily activities. If successful, this could mean a significant improvement in quality of life for older adults with HIV, allowing them to regain some of the physical abilities they may have lost. However, it’s important to remember that this is still a trial, and results will take time to analyze. The hope is that these findings could lead to new treatments that help older adults with HIV live healthier, more active lives.
What this means for you: A new drug combo could help older adults with HIV regain strength and improve their quality of life.
View Original Abstract ↓
Status: ACTIVE_NOT_RECRUITING | Phase: PHASE2
Condition(s): HIV, Frailty, Prefrail, Aging Problems
Intervention(s): Dasatinib (DRUG), Quercetin (DRUG), Placebo - Dasatinib (OTHER), Placebo - Quercetin (OTHER)
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression.
Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects.
The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Primary Outcome(s): Occurrence of Grade 2 or higher adverse events (AEs) after initiation of study treatment.; Occurrence of premature treatment discontinuations.; Absolute change in gait speed on 4-meter walk.
Enrollment: 82 (ACTUAL)
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Start: 2025-12-04 | Primary Completion: 2026-11-29
